Alexza Pharmaceuticals To Present AZ-104 Phase 2a Clinical Data At The American Headache Society Annual Scientific Meeting
Jun 30th 2008Drug InformationHeadache / Migraine
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marriott Boston Copley Place in Boston, MA.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
